We’ve got to focus on Europe today and change some of our strategy in Europe, which we’re doing upon legalization, but focus on that medical business, but there’s a whole third market out there where they’re using cannabis as recreational, but buying it from the medical market and really focus on integrating now our CC Pharma business from a distribution standpoint. We’ve been successful with SweetWater. We’ve been successful with Breckenridge. The Montauk was a great asset for us to buy these niche beer businesses. And we’ve seen a great turnaround in our wellness business. So right now, in the U.S., we’re going to focus our acquisitions on buying adjacencies to the cannabis business. And if it’s ’24, ’25 or ’26, we’re not depending and sitting here waiting for Congress and the Senate to make decisions, and that is ultimately the results of going to affect the results of our business because I don’t want the effects of the results for our shareholders and our business be affected by politicians in Washington.
Operator: Our next question is from the line of Frederico Gomes with ATB Capital. Please proceed with your question.
Frederico Gomes: Just on the price environment in Canada, in 2022, we continue to see price compression. And obviously, as you mentioned, it has been almost unsustainable with excise taxes and so on. So my question is, do you expect any significant shift in Canada in 2023 in terms of pricing what could be the driver there? Is there any chance of that happening? Or do you believe that sort of price pressure will persist in 2023? Thanks.
Irwin Simon: So, I’m going to answer it partially, and then I’ll turn it over to Blair, and we can also talk about what we see in price compression everywhere else. I think cannabis is probably the only product out there where inflation hasn’t hit, okay? But again, that’s going to — and quarter-over-quarter, we’ve seen very little price compression out there. Year-over-year, we’ve seen almost $12 million from our standpoint. But the focus got to be building brands and brands do have to matter. At the same time, innovation got the matter, and that’s coming out with different potencies different types of products and innovating product, and that’s ultimately where you’re going to get the right pricing. And as you’re going to see other LPs go away, you’re going to ultimately see that too. And us being that low-cost producer will be able to be that price leader in the marketplace out there. Blair, do you want to add anything to that?
Blair MacNeil: Yes. So just overall, I would say it is going to be unlikely to see rate changes in pricing over the next 12 months. What you may see is category mix, a little bit of a shift to pre-roll which can improve the pricing from a mix standpoint or just volume across provinces. And then finally, to Irwin’s point, on the brand side, I referenced it in my answer earlier. But if you look at how we’re approaching innovation, we’re really thinking about those consumer segments where we have opportunity to grow and those sub-segments within category. RIFF is a great example of where we’re entering into a category with higher-quality offering, which will drive some average revenue up, but it will take time. I would say from a when do we see it changing?
I think I’ve been saying for 12 months that as we see industry consolidation as we see the number of LPs start to go down or normalize and the inventory levels over the industry normalized. I think then you’ll start to see a real sustainable push in terms of being able to build rate into your economics year-over-year.
